Latest Deals

Shares in J&J were up 1.6% at the market close on 30 November. Image credit: Shutterstock/Michael Vi.

Johnson & Johnson (J&J) MedTech has made an upfront payment of $400m to acquire the privately held company Laminar, a US-based developer of a heart implant that reduces the chance of stroke. The completed deal, which also includes additional potential clinical and regulatory milestone payments, will see Laminar join J&J as part of its Biosense Webster division, according to a 30 November press release.

Medical technology company Smith+Nephew has agreed to acquire Agili-C implant developer CartiHeal, in a deal worth up to $330m. Under the agreement, Smith+Nephew will initially make a cash payment of $180m to CartiHeal at the closing of the transaction. The medical technology company will make an additional payment of up to $150m based on financial performance.

EndoQuest Robotics has secured $42m in a C-1 preferred financing round for advancing its endoluminal robotics technology. The robotic system offers flexibility and precision, along with improved patient outcomes. It is designed to navigate and conduct procedures within the luminal spaces of the body. Legacy EndoQuest investors CE Ventures and McNair Interests led the financing round and were joined by new investor Puma Venture Capital.

Nevro has acquired medical technology company Vyrsa Technologies in a deal valued at around $75m. As per the transaction, Nevro made a $40m payment at closing and committed up to an additional $35m, either in cash or stock, based on reaching specific milestones in development and sales. Vyrsa specialises in providing a less invasive treatment for individuals with chronic SI joint pain. Established in 2021, it is claimed to be the only SI joint company that produces and supports a complete portfolio of FDA-approved SI joint fusion devices.